Highlights

  • EMvision Medical Devices shares rose 0.98% to AUD 1.54 on 15 July 2026 following its June-quarter clinical and cash flow update.
  • The pivotal validation trial for the emu point-of-care brain scanner moved beyond key enrolment milestones across its training and primary analysis cohorts.
  • EMvision ended the quarter with AUD 17.1 million in cash and a further AUD 4.6 million of non-dilutive funding remaining under existing grant programs.
  • The First Responder aeromedical study completed enrolment across 14 transfers involving 12 airstrips located between 125 kilometres and 371 kilometres from Adelaide Airport.

EMvision Medical Devices Limited (ASX:EMV) shares edged 0.98% higher to AUD 1.54 during the morning session on 15 July 2026 after the company released its quarterly activities and cash flow report for the three months ended 30 June 2026. The update outlined progress across the company’s pivotal clinical trial, development of additional stroke-detection capabilities, pre-hospital device studies and grant-backed commercialisation programs. The stock remained approximately 10.98% lower over the preceding year despite the positive movement during the session.

EMvision is developing portable neurodiagnostic scanning systems intended to assist clinicians in diagnosing stroke and other time-sensitive brain conditions closer to the point of care. Its product pipeline includes the emu bedside brain scanner and the smaller First Responder device designed for use in ambulances, aircraft and other pre-hospital environments. The company’s initial target is acute stroke assessment, while traumatic brain injury represents a planned secondary clinical application.

Pivotal Trial Moves Beyond Key Enrolment Levels

The pivotal validation trial for EMvision’s first-generation emu brain scanner remained one of the company’s central priorities during the June quarter. Recruitment moved beyond key milestones across both the training cohort and the primary analysis cohort, with enrolment continuing across active hospitals in the United States and Australia.

EMvision said recruitment activity had increased following several acceleration measures introduced during the quarter. The scanner has continued to fit into participating hospitals’ established stroke-response procedures, and no device-related adverse events had been reported as of the announcement date.

The company is targeting full enrolment from late calendar year 2026 to early calendar year 2027. Sequential readouts from the trial cohorts are expected to follow after recruitment has been completed and the relevant data has undergone independent analysis.

The trial is a prospective, blinded and multi-centre diagnostic performance study intended to support an application for US Food and Drug Administration De Novo clearance. Its primary objective is to demonstrate haemorrhage-detection sensitivity and specificity above 80%.

EMvision remains blinded to certain trial information until recruitment is completed. The company said the study is collecting data in a way that may allow additional diagnostic features to be evaluated without requiring another complete validation trial.

Several academic and tertiary hospitals are recruiting patients into the study. The US sites include Mayo Clinic in Jacksonville, Mount Sinai Hospital, Mount Sinai West, Ronald Reagan UCLA Medical Center, Memorial Hermann–Texas Medical Center and Memorial Hermann–Memorial City.

Australian recruitment sites include Royal Melbourne Hospital and Liverpool Hospital. Princess Alexandra Hospital is also transitioning from the company’s Continuous Innovation Study into the pivotal trial, using its trained staff, existing site preparation and prior familiarity with the emu platform.

EMvision is additionally preparing to onboard further US academic medical centres that have been referred to the company. Management said the referrals reflected increasing clinical interest in the trial and its portable brain-scanning technology.

Ischaemia Endpoint Could Broaden Initial Product Utility

A further development during the quarter was EMvision’s preparation to include an acute ischaemia detection endpoint within the pivotal validation trial.

The company has progressed this feature through its Continuous Innovation Study and now plans to discuss the proposed clinical claims and performance thresholds with the FDA through an upcoming pre-submission, or Q-Sub, meeting. A corresponding amendment to the trial protocol is also planned.

Patients with ischaemic stroke are already being enrolled in the pivotal trial. As a result, EMvision expects the required modifications to be incremental and capable of using data already collected through existing hospital workflows.

The company noted that the sample size may require a limited adjustment to ensure the ischaemic subgroup satisfies its statistical targets.

Stroke can result either from bleeding within the brain or from an interruption of blood flow caused by a blocked vessel. The treatments used for these conditions differ, meaning that early classification is important when clinicians are making time-sensitive decisions.

According to EMvision, the ability to detect and distinguish both haemorrhagic and ischaemic stroke through a single point-of-care scan could expand the emu scanner’s clinical role from its initial commercial release.

The additional endpoint may also provide a clinical and regulatory foundation for the company’s second-generation First Responder scanner, which is intended to operate before a patient arrives at hospital.

Continuous Innovation Study Supports Algorithm Development

Alongside the pivotal trial, EMvision continued its Continuous Innovation Study, which is designed to generate proprietary clinical datasets and assist with the refinement of artificial intelligence models.

The study includes patients with suspected stroke and traumatic brain injury. Data generated through the program is being used to develop features relating to acute ischaemia and large vessel occlusion detection, while also supporting broader product-platform development.

The study’s participating hospital network is changing as Princess Alexandra Hospital moves into the pivotal trial. Box Hill Hospital is joining the Continuous Innovation Study in its place, while additional sites are being prepared to increase clinical data generation.

EMvision also received independent scientific exposure shortly after the quarter ended. Research into its portable radio-frequency brain-scanning technology and proprietary deep-learning methods was published in npj Digital Medicine, which is part of the Nature portfolio.

The paper drew on information from the earlier EMView study and examined machine-learning techniques developed to identify diagnostic signals from constrained datasets.

Previously reported performance on unseen EMView data showed 92% sensitivity and 85% specificity when distinguishing haemorrhagic from non-haemorrhagic episodes. For ischaemic versus non-ischaemic episodes, the reported sensitivity was 95% and specificity was 80%.

The company cautioned that development-study results from a limited dataset may differ from those generated through a larger prospective and controlled validation program.

Beyond stroke classification, the research identified a consistent ordering of relative dielectric properties across haemorrhagic stroke, ischaemic stroke, stroke mimics and healthy states. EMvision said the research contributed new scientific understanding of brain tissue’s dielectric behaviour.

The same core algorithm pipeline supports both the emu scanner and the second-generation First Responder device. EMvision has filed a patent application covering intellectual property generated through its research and development activities.

Regional Hospital Study Targets Second-Half Launch

EMvision’s Regional Benefits Study is progressing toward a planned launch in the second half of calendar year 2026.

The study is funded through the Cooperative Research Centres Projects program and is being undertaken with the Australian Stroke Alliance, Titan Pre-Hospital Innovation and South Australia’s Rural Support Service.

Site selection was at an advanced stage at quarter-end. Work covering protocol development, deployment within hospitals and integration with telehealth systems was also progressing.

The company received a further AUD 0.4 million grant instalment after meeting the relevant milestones during the quarter.

The study will examine how the emu scanner may be used in regional hospitals where patients can face lengthy travel times before receiving conventional brain imaging and a definitive diagnosis.

The planned model combines bedside scanning with remote input from stroke neurologists through telemedicine. EMvision intends to assess whether this approach can accelerate clinical decisions for patients in regional areas.

Management views the study as potentially relevant beyond Australia because similar diagnostic delays affect rural and remote communities in other countries.

Aeromedical Study Completes Enrolment

EMvision also completed enrolment in its First Responder Air Deployment Study during the quarter.

The project was conducted in partnership with the Royal Flying Doctor Service, the Australian Stroke Alliance and the South Australian Ambulance Service. It assessed the prototype scanner across clinics, aircraft, tarmacs, hangars and remote runways.

Flight compatibility was evaluated across all 14 aeromedical transfers included in the study. These transfers involved 12 airstrips located between 125 kilometres and 371 kilometres from Adelaide Airport.

The company reported that scans were completed quickly and were well tolerated by patients. Flight nurses and participating patients also assessed the prototype favourably during real-world operation.

A manuscript is now being prepared for potential peer-reviewed publication. Operational findings from the study are also being incorporated into the production design of the First Responder device.

The study addresses an intended use case for patients in remote locations where access to hospital-based imaging can be delayed. EMvision is developing the scanner to assist with earlier assessment and transfer decisions during aeromedical retrieval.

Mobile Stroke Unit Program Nears Stage-One Reporting

Stage one of the Mobile Stroke Unit study with Ambulance Victoria, Royal Melbourne Hospital and the Australian Stroke Alliance is approaching completion.

Recruitment and reporting are expected to conclude during the current quarter.

The study is evaluating the First Responder prototype within a Mobile Stroke Unit involved in clinical research and hyperacute stroke care. EMvision said the first stage would provide information about workflow integration and device usability during urgent pre-hospital patient encounters.

Preliminary observations were described as consistent with themes seen in the aeromedical program, while offering additional insight into stroke-response requirements in an urban environment.

Together, the aeromedical and Mobile Stroke Unit programs are intended to build evidence across different emergency settings, ranging from densely populated metropolitan areas to regional and remote locations.

Road Ambulance Testing Enters Preparation Phase

Preparations also advanced for a study involving the production-equivalent First Responder scanner in road ambulances.

A usability workshop was held during the quarter to gather feedback from prospective operators on setting up and using the device within the space limitations of an ambulance.

The feedback is informing the design of the planned study and the commercial device.

Road ambulances represent a higher-volume emergency setting than specialised aeromedical and Mobile Stroke Unit operations. Testing in this environment is therefore expected to add another layer of practical evidence concerning workflow, handling and deployment.

EMvision is using findings from all three pre-hospital programs to finalise the production-equivalent design. Development priorities include diagnostic performance, reduced weight, lower component numbers, simplified assembly and decreased manufacturing costs.

The company is aiming to create a system suited to road ambulance, aeromedical and other pre-hospital applications.

Military and Emergency Medicine Engagement Expands

During the quarter, EMvision participated in the Medical Technology Enterprise Consortium, which works with the US Department of Defense to accelerate medical technology development.

The engagement provided the company with access to military health stakeholders focused on traumatic brain injury and care delivered in field or austere environments where conventional imaging may be unavailable.

EMvision said these conditions align with the intended use of its portable First Responder scanner and that it would continue examining opportunities in defence and military health alongside its clinical partners.

The company has also had an abstract accepted for the 2026 Military Health System Research Symposium, scheduled for 3–6 August 2026 in Kissimmee, Florida.

EMvision additionally attended the International Conference on Emergency Medicine in Germany, where its portable scanners were presented as a possible way to reduce diagnostic delays in stroke and traumatic brain injury.

Cash Position Supports Ongoing Clinical Programs

EMvision ended the quarter with AUD 17.1 million in cash, compared with AUD 18.4 million at the beginning of the period.

Net cash used in operating activities was approximately AUD 1.27 million. This included AUD 1.03 million of external research and development expenditure, AUD 1.87 million in staff costs and approximately AUD 0.72 million in administration and corporate expenses.

Research and development spending decreased from AUD 1.08 million in the March quarter. The previous period included initial contract research organisation and site costs for the pivotal trial, along with completion of clinical-trial device manufacturing.

The company received approximately AUD 2 million in non-dilutive funding during the quarter. This comprised an AUD 1.17 million Industry Growth Program milestone payment, an AUD 0.4 million Cooperative Research Centres Projects grant payment and a final AUD 0.4 million Australian Stroke Alliance payment.

A further AUD 4.6 million remains available under existing grant programs. This includes AUD 2.8 million under the AUD 5 million Industry Growth Program and AUD 1.8 million under the AUD 3 million Cooperative Research Centres Projects program.

Based on the June-quarter operating cash outflow, EMvision reported an estimated 13.44 quarters of available funding. The company had no loan facilities or other financing facilities drawn at quarter-end.

Payments of AUD 0.206 million were made to related parties during the period. These consisted of directors’ salaries, fees and superannuation.

What Does the Update Mean for EMvision?

The June-quarter report showed progress across several clinical and product-development workstreams rather than relying on a single trial milestone.

Recruitment in the FDA-enabling emu validation study moved beyond key levels, while preparations for an ischaemia endpoint may broaden the scanner’s intended diagnostic role if successfully validated and cleared.

At the same time, the First Responder program generated practical information across aeromedical and Mobile Stroke Unit settings, with road ambulance testing being prepared as the next stage.

The company’s AUD 17.1 million cash balance and remaining AUD 4.6 million in grant funding provide resources for continued clinical, regulatory and product-development activity. Investors are likely to monitor the pace of pivotal-trial enrolment, FDA discussions concerning the ischaemia endpoint, the launch of the Regional Benefits Study and further First Responder study results.